Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975667 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL2320202 | 0.88 | USP2 (0.47) | USP2SMN1; SMN2TSHRALOX15ATM | |
| SCHEMBL28587906 | 0.83 | USP2 (0.43) | USP2SMN1; SMN2TSHRALOX15ATM | |
| SCHEMBL21644242 | 0.80 | CYP4F2 (0.47) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL22323275 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL21058505 | 0.79 | CHRM2 (0.32) | USP2CYP4F2CYP4A11 | |
| SCHEMBL22284343 | 0.79 | CYP4F2 (0.52) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 | |
| SCHEMBL6749647 | 0.78 | USP2 (0.43) | USP2SMN1; SMN2TSHRALOX15HPGD | |
| SCHEMBL18044505 | 0.78 | KMT2A (0.35) | USP2SMN1; SMN2TSHR | |
| SCHEMBL1709866 | 0.76 | USP2 (0.50) | USP2SMN1; SMN2CYP4F2CYP4A11NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | TUCKER HOWARD | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021038-A1 | Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5 | CCR5, CXCR1, CCR2 | USP2 4378/4885SMN1; SMN2 4558/4885CYP4F2 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.